Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD7 CAR-T + autologous hematopoietic stem cell transplantation
- Development stage
- Unknown
- Lead developer
- Zhengzhou University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD7 CAR-T + autologous hematopoietic stem cell transplantation is an investigational combination therapy being evaluated by Zhengzhou University for the treatment of relapsed or refractory CD7-positive T-cell lymphomas. The treatment protocol integrates high-dose chemotherapy (typically the BEAM regimen) followed by autologous hematopoietic stem cell transplantation (ASCT) to rescue the bone marrow, and the subsequent infusion of chimeric antigen receptor (CAR) T cells engineered to target the CD7 antigen. This sequential approach is intended to maximize tumor debulking through intensive conditioning while providing a targeted cellular immunotherapy to eradicate residual lymphoma cells and prevent relapse. The therapy is currently being studied in a Phase I/II clinical trial to determine the maximum tolerated dose and preliminary efficacy.
- Other names
- CD7 CAR-T + ASCTCD7 CAR-T combined with autologous hematopoietic stem cell transplantationCD-7 CAR-T combined with autologous hematopoietic stem cell transplantationCD 7 CAR-T combined with autologous hematopoietic stem cell transplantationCD7-targeted chimeric antigen receptor T cells combined with autologous stem cell transplantationCD-7-targeted chimeric antigen receptor T cells combined with autologous stem cell transplantationCD 7-targeted chimeric antigen receptor T cells combined with autologous stem cell transplantation
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on CD7 CAR-T + autologous hematopoietic stem cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD7 CAR-T + autologous hematopoietic stem cell transplantation.